

## Commentary

### Quality and Patient Safety

## In Response: Statins Not Beneficial in Most Chest Pain Admits

Justin Moore, M.D.

University of Kansas School of Medicine-  
Wichita

Department of Internal Medicine

While I share Dr. Mosley's skepticism at some of the recent hope for 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors (statins) as treatment for non-vascular illnesses, I disagreed with his assertion that lipid levels should not be evaluated in the emergency department. Though Dr. Mosley's cynicism regarding pharmaceutical companies' influence on research findings may be well founded<sup>1</sup>, it should be pointed out that large, independently funded studies showing the mortality benefit of lipid reduction<sup>2</sup> and lipid reduction specifically by statins<sup>3</sup> in high-risk populations have been in the literature since the 1980s.

When a statin-naïve patient presents with chest pain, his or her cardiovascular risk cannot be evaluated fully without knowledge of lipid status, a position endorsed by the National Cholesterol Education Program.<sup>4</sup> The point that low-risk patients may not benefit from statin therapy is moot until all the relevant data are known. Young people with heterozygous familial hypercholesterolemia, a common condition whose mortality can be reduced with cholesterol-lowering therapy, present to physicians every day complaining of chest discomfort.

In people already prescribed statins, compliance, even among high-risk patients, is poor.<sup>5</sup> Beside directly questioning the patient, a method whose poor reliability is highlighted by the recent national movement toward "medication reconciliation", adherence can be judged in only one way: calculation or direct measurement of the serum low-density lipoprotein (LDL) level. Calculation of the LDL can be problematic because, as Dr. Mosley points out, a non-fasting specimen may be incalculable secondary to high serum triglyceride content. If the patient is non-fasting, though, the "non-HDL" cholesterol level serves as a suitable alternative.<sup>6</sup> In the near future, measurement of the LDL level likely will be replaced by measurement of apolipoprotein B, which will eliminate the need for a fasting specimen.<sup>7</sup>

While it is true that the immediate post-myocardial infarction effect of statin therapy has not lived up to its initial promise, the long-term effect of statins on mortality in high-risk populations is so profound, roughly a 1% decrease in five-year mortality for every 1 mg/dl reduction in LDL in high risk groups<sup>4</sup>, that adherence to therapy must be evaluated.

Hypercholesterolemia is one of the primary modifiable risk factors for cardiovascular death. A lipid panel, fasting or not, is a relatively inexpensive test that aids in risk-stratification of patients presenting with chest pain, helps evaluate compliance in people already prescribed statins, and is indispensable to the patient's primary care provider, hospitalist, cardiologist, or endocrinologist.

### References

- <sup>1</sup> Bero L, Oostvogel F, Bacchetti P, Lee K. Factors associated with findings of published trials of drug-drug comparisons: Why some statins appear more efficacious than others. *PLoS Med* 2007; 4:e184.

- <sup>2</sup> Blankenhorn DH, Nessim SA, Johnson RL, Sanmarco ME, Azen SP, Cashin-Hemphill L. Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts. *JAMA* 1987; 257:3233-3240.
- <sup>3</sup> Brown G, Albers JJ, Fisher LD, et al. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. *N Engl J Med*. 1990; 323: 1289-1298.
- <sup>4</sup> Grundy SM, Cleeman JI, Bairey Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. *Circulation* 2004; 110:227-239.
- <sup>5</sup> Vinker S, Shani M, Baevsky T, Elhayany A. Adherence with statins over 8 years in a usual care setting. *Am J Manag Care* 2008; 14: 388-392.
- <sup>6</sup> Dungan KM, Guster T, DeWalt DA, Buse JB. A comparison of lipid and lipoprotein measurements in the fasting and nonfasting states in patients with type 2 diabetes. *Curr Med Res Opin* 2007; 23:2689-2695.
- <sup>7</sup> Brunzell JD, Davidson M, Furberg CD, et al. Lipoprotein management in patients with cardiometabolic risk: Consensus Conference Report from the American Diabetes Association and the American College of Cardiology Foundation. *J Am Coll Cardiol* 2008; 51:1512-1524.

*Keywords:* statin, myocardial infarction, emergency service, commentary